glp-1 success is more than the medication—it's habits, consistency, and support. Small changes every day lead to big results. 💪 Believe in yourself and stay committed! ✨ Effective Weight Management Strategies: Lasting

Only one in 12 remain on a GLP-1 drug for obesity at three years owenhaskins Jun 26, 2025 2 min read Only 8% of individuals (or one in 12) initiating a glucagon-like peptide-1 (GLP-1) agonist drug for obesity without diabetes continued to do so at three years, according to the latest real-world research from Prime Therapeutics (Prime)

If pancreatitis is confirmed during GLP-1 therapy, treatment discontinuation is standard practice

Weight loss stalls despite good adherence

Regulatory agencies, including the European Medicines Agency and the World Health Organization, have issued warnings regarding NAION as a potential risk associated with semaglutide medications

7 Unlike food categories that can be reformulated around protein or fiber, alcohols core product is inherently caloric, leaving companies with few levers beyond low- and no-alcohol extensions